RarePipelinepeopleInnovationCollaborationCareersFinance Advance treatment Skip to main contentSkip to navigationSkip to search
Hansa Biopharma
HNSA (, %) SEK
Hansa Biopharma
Financial documents

Shareholders

Shareholders

Top 10 shareholders as of June 31, 2022

NameNumber of sharesOwnership in pct
Redmile Group, LLC5 380 86312.1%
Fjärde AP-Fonden (AP 4)2 207 3974.9%
Nexttobe AB2 155 3794.8%
Invesco Advisers, Inc.1 973 9314.4%
Olausson, Thomas1 820 5004.1%
Försäkrings AB Avanza Pension1 743 2014.0%
Tredje AP-Fonden (AP 3)1 389 6503.1%
The Vanguard Group, Inc.1 223 8392.7%
Schroder Investment Management, LTD888 1322.0%
C WorldWide Asset Management
799 7491.8%
Other25 005 47756.1%
Outstanding shares in total44,588,118100.0%

Source: IHS Markit/IPREO compiled and processed data from various sources, including Euroclear, Morningstar, Factset and the Swedish Financial Supervisory Authority (Finansinspektionen).

Hansa Biopharma had approximately 18,000 shareholders as of March 31, 2022.

Classification of ownership as per Dec 31, 2021

Region

60%
23%
13%
4%

Category

50%
35%
10%
5%